CD47 and acute myeloid leukemia: Magrolimab (Hu5F9-G4), a humanized anti-CD47-IgG4 monoclonal antibody, has demonstrated an early, promising efficacy when administered as a priming/intra-patient dose escalation regimen (1–30 mg/kg weekly) in combination with a standard dose azacitidine for patients with AML [87].